Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute non-alcoholic caffeinated beverage consumption as a trigger for cryptogenic ischemic stroke in the young: findings from the SECRETO study.

Journal of neurology·2026
Same author

Sex-specific associations between midlife body mass index and later-life left atrial enlargement in the Hordaland health study.

Heart (British Cardiac Society)·2026
Same author

Translation and validation of the Norwegian ABCD Risk Questionnaire to assess cardiovascular disease knowledge and risk perception prior to myocardial infarction.

BMJ open·2026
Same author

Phase 1 dose-escalation trial combining sulfasalazine and stereotactic radiosurgery in patients with recurrent glioblastoma.

Redox biology·2026
Same author

Prevention of heart failure.

European heart journal·2026
Same author

Association Between Physical Activity and Cryptogenic Ischemic Stroke in Young Adults: A Case-Control Study.

European journal of neurology·2026

Related Experiment Video

Updated: Jun 26, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Left ventricular long-axis function in myasthenia gravis.

Jone Furlund Owe1, Einar Skulstad Davidsen, Geir Egil Eide

  • 1Dept. of Neurology, Haukeland University Hospital, 5021 Bergen, Norway. jone.furlund.owe@helse-bergen.no

Journal of Neurology
|January 22, 2009
PubMed
Summary
This summary is machine-generated.

Myasthenia gravis (MG) may affect heart function, with early diastolic function impaired before pyridostigmine. This impairment resolved after treatment, suggesting pyridostigmine-responsive cardiac changes in MG patients.

More Related Videos

Quantification of Mouse Heart Left Ventricular Function, Myocardial Strain, and Hemodynamic Forces by Cardiovascular Magnetic Resonance Imaging
11:13

Quantification of Mouse Heart Left Ventricular Function, Myocardial Strain, and Hemodynamic Forces by Cardiovascular Magnetic Resonance Imaging

Published on: May 24, 2021

Evaluation of Left Ventricular Structure and Function using 3D Echocardiography
06:34

Evaluation of Left Ventricular Structure and Function using 3D Echocardiography

Published on: October 28, 2020

Related Experiment Videos

Last Updated: Jun 26, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Quantification of Mouse Heart Left Ventricular Function, Myocardial Strain, and Hemodynamic Forces by Cardiovascular Magnetic Resonance Imaging
11:13

Quantification of Mouse Heart Left Ventricular Function, Myocardial Strain, and Hemodynamic Forces by Cardiovascular Magnetic Resonance Imaging

Published on: May 24, 2021

Evaluation of Left Ventricular Structure and Function using 3D Echocardiography
06:34

Evaluation of Left Ventricular Structure and Function using 3D Echocardiography

Published on: October 28, 2020

Area of Science:

  • Cardiology
  • Neurology
  • Medical Diagnostics

Background:

  • Myasthenia gravis (MG) primarily impacts skeletal muscles.
  • Cardiac involvement in MG is suspected but not well-defined.
  • Acetylcholine-esterase inhibitors like pyridostigmine are standard MG treatments.

Purpose of the Study:

  • To evaluate left ventricular long-axis function in MG patients versus controls.
  • To investigate the effect of pyridostigmine on cardiac function in MG.
  • To determine if MG is associated with cardiac dysfunction.

Main Methods:

  • Utilized tissue Doppler imaging and conventional echocardiography.
  • Compared left ventricular long-axis function in MG patients and healthy controls.
  • Assessed cardiac function before and after pyridostigmine administration.

Main Results:

  • MG patients showed lower early diastolic atrioventricular-plane velocity and peak systolic strain before pyridostigmine.
  • These differences normalized post-pyridostigmine administration.
  • Multivariate analysis, adjusting for blood pressure, negated the association between MG and impaired long-axis function. Conventional measures showed no significant differences.

Conclusions:

  • No definite cardiac involvement in MG patients without pre-existing heart disease was demonstrated.
  • Pyridostigmine-responsive alterations in cardiac muscle function may exist in MG patients.
  • Further research is needed to fully understand the cardiac implications of MG.